Antibody-drug Conjugate Information
General Information of This Antibody-drug Conjugate (ID: DRG0MRJEG)
| ADC Name |
REGN5093-M114
|
|||||
|---|---|---|---|---|---|---|
| Synonyms |
REGN5093-M114
Click to Show/Hide
|
|||||
| Organization |
Regeneron Pharmaceuticals (Originator)
|
|||||
| Drug Status |
Phase 1 (discontinued)
|
|||||
| Drug-to-Antibody Ratio |
3.2
|
|||||
| Structure |
|
|||||
| Antibody Name |
REGN5093
|
Antibody Info | ||||
| Antigen Name |
Hepatocyte growth factor receptor (MET)
|
Antigen Info | ||||
| Payload Name |
Maytansine derivative M24
|
Payload Info | ||||
| Payload Target |
Microtubule (MT)
|
Target Info | ||||
| Linker Name |
SC-Val-Cit-PABC
|
Linker Info | ||||
| Conjugate Type |
Random Lysines
|
|||||
2027 Update
The disease landscape of This ADC
2027 Update
The clinical trial pipelines of This ADC
| Indication | Phase 1 | Phase 2 | Phase 3 | Approved | ||
|---|---|---|---|---|---|---|
| Lung cancer |
1 Trials
|
General Information of The Activity Data Related to This ADC
Full List of Activity Data of This Antibody-drug Conjugate
Identified from the Human Clinical Data
| Experiment 1 Reporting the Activity Date of This ADC | [1] | ||||
| Patients Enrolled |
Eligible: Advanced NSCLC (no standard options), ECOG 0-1, MET overexpression (fresh/archival biopsy ≤6 months old), measurable lesion (s) (expansion), adequate organ function. Excluded: Recent systemic therapy (<2 weeks/5 half-lives), unresolved toxicities (>grade 1), active CNS disease, uncontrolled infections (HIV/HBV/HCV), or concurrent malignancy. Prior irradiation requires documented progression in irradiated lesions.
Click to Show/Hide
|
||||
| Administration Dosage |
Cohorts A and B: REGN5093-M114 monotherapy. Cohort C: REGN5093-M114+cemiplimab combination.
|
||||
| Related Clinical Trial | |||||
| NCT Number | NCT04982224 | Clinical Status | PHASE1|||PHASE2 | ||
| Clinical Description | A Phase 1/2 Study of REGN5093-M114 (METxMET Antibody-Drug Conjugate) in Patients With MET Overexpressing Advanced Cancer | ||||
| Primary Endpoint |
Phase 1 dose escalation will assess safety through DLTs (28-day window), TEAEs, SAEs, treatment discontinuations, deaths, and CTCAE grade 3+ lab abnormalities over ~2 years. Pharmacokinetics include serum concentrations of REGN5093-M114 (total/conjugated), plasma M24 levels, and cemiplimab concentrations (Cohort C). Phase 2 expands ORR evaluation.
|
||||
| Other Endpoint |
Efficacy/Safety (both phases): ORR, TEAEs, SAEs, treatment-limiting toxicities, lab abnormalities, PK of REGN5093-M114/M24/cemiplimab (Cohort C), and ADA incidence/titer against cemiplimab/REGN5093-M114. Tumor response endpoints (DOR, DCR, TTR, PFS, OS) are tracked over 2 years.
|
||||
References